Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BxC-I17e in moderate to severe atopic dermatitis
NCT06055361Phase 1Recruiting
- Sponsor
- Brexogen
- Start
- Apr 2023
- Primary completion
- Mar 2026
- Modality
- Liposomes, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BRE-AD01 in atopic dermatitis (AD) (4 arms), sponsored by Brexogen. Primary endpoint: Treatment-Emergent Adverse Events at 26 weeks. Started Apr 2023; status: recruiting.
02
Drugs
BRE-AD01
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06055361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06055361.